Immune adherence hemagglutination, SPRIA, and ELISA have all been used in the serodiagnosis of acute viral hepatitis type A, but they require testing of acute-and convalescentphase sera for anti-HAV (4). We have therefore evaluated an ELISA for the detection of immunoglobulin M (IgM) anti-HAV based on the principle described by Duermeyer and van der Veen (5).
In 1973 Feinstone et al. (6) described the demonstration of hepatitis A virus (HAV) and antibody to HAV (anti-HAV) by immune electron microscopy. Since then, different methods, such as complement fixation (18) , immune adherence hemagglutination (15, 16) , solid-phase radioimmunoassay (SPRIA) (7, 19) , and enzyme-linked immunosorbent assay (ELISA) (10, 12, 20) , have been used to detect HAV and anti-HAV.
Immune adherence hemagglutination, SPRIA, and ELISA have all been used in the serodiagnosis of acute viral hepatitis type A, but they require testing of acute-and convalescentphase sera for anti-HAV (4) . We have therefore evaluated an ELISA for the detection of immunoglobulin M (IgM) anti-HAV based on the principle described by Duermeyer and van der Veen (5).
MATERIALS AND METHODS
Patients. In three patients with acute viral hepatitis type A, serial sera were collected and tested for anti-HAV and IgM anti-HAV. Acute-phase sera from a group of 48 patients with acute viral hepatitis previously serologically confirmed as type A (17 patients), type B (24 patients), type A + B (1 patient), and type non-A non-B (6 patients) (11) were tested for IgM anti-HAV.
Sera from 98 of 225 Danish blood donors, in which anti-HAV had previously been demonstrated by blocking ELISA, and from 10 donors negative for anti-HAV (13) were tested for IgM anti-HAV. In addition, 55 sera randomly selected among sera found positive for rheumatoid factor at the laboratory for Autoimmune Diseases, Statens Seruminstitut, were tested for anti-HAV, IgM anti-HAV, and IgM antibodies to rubella.
Methods. IgM anti-HAV was detected by ELISA performed in microtiter plates (Dynatech, catalog no. 1-220-25) (Fig. 1) After the plates were washed an additional three times, 25 ,ul of a stool extract containing HAV was added, and the plates were incubated overnight at 4'C. After three washings with PBS-Tween 20, 50 1I of a peroxidase-conjugated IgG prepared from a human convalescent-phase serum as described previously (12) and diluted in 50% human serum was added, and the plates were incubated for 2 h at room temperature. The human serum was a pool from 34 blood donors found to be negative for anti-HAV. stopped by adding 75 ul of 2 M sulfuric acid, and after the addition of 75 yl of PBS, bringing the total volume to 250 ,ul, the extinction at 493 nm was measured in a spectrophotometer with a rapid sampling microcuvette (Gilford model 250).
All the plates included a positive control, and as negative control a serum positive for anti-HAV in high titer but negative for IgM anti-HAV was employed. In addition, serial sera taken 1, 2, 3, and 6 months after the onset of acute hepatitis type A were always included in one of the plates. A serum was considered to contain IgM anti-HAV if the extinction at 493 nm for the serum divided by the extinction at 493 nm for the negative control serum (P/N) was above 2.1. The exact titer was calculated by interpolation from the highest 10-fold dilution giving a P/N value above 2.1 to the following dilution giving a lower P/N value, using 2.1 as cutoff. The negative control serum gave an extinction at 493 nm of about 0.05, and the positive serum gave about 0.5.
Anti-HAV was measured in a competition ELISA (11) (Fig. 2) , a modification of the originally described blocking ELISA (12) . Rheumatoid factor was detected by the Rose-Waaler test, and IgM antibodies to rubella were detected by ELISA (Fig. 3) (4, 11) or testing dilutions of paired acute-and convalescent-phase sera in one of the tests and demonstrating seroconversion or a fourfold titer rise (11) . Frequently no such titer rise can be demonstrated by SPRIA or ELISA if the first serum is not taken very early during the disease and the second serum more than 4 weeks later (11, 17) . It is therefore of great value to have a test for IgM anti-HAV for the serodiagnosis of acute hepatitis type A.
Separation of IgM and IgG by sucrose gradient centrifugation and subsequent testing for anti-HAV has been used previously, but the process is rather time consuming (9, 17).
Bradley et al. (2) have described a modification of their SPRIA for anti-HAV, so that IgM and IgG antibodies could be distinguished, but the principle has not been evaluated further.
We have found that our modification of the ELISA for detecting IgM anti-HAV, originally described by Duermeyer and van der Veen (5), is easy to perform and gives reproducible results. 10, 1979 In testing a group of patients with acute hepatitis serologically confirmed as type A, B, or non-A non-B, the ELISA for IgM anti-HAV showed a high accuracy for both positive and negative results. This was further confirmed by the failure to demonstrate IgM anti-HAV in sera from normal blood donors positive for anti-HAV and in sera with a high titer of anti-HAV collected more than 3 months after the onset of acute hepatitis type A.
With other ELISA and SPRIA tests for IgM antibody for different viral diseases, a different principle has generally been used (1, 3, 8, 21) . The serum to be tested is added to an antigencoated solid phase, followed by conjugated antihuman IgM (Fig. 3) . In this system IgM and IgG antibodies compete for the antigenic sites, thus making it difficult to demonstrate IgM antibodies in the presence of larger amounts of IgG antibodies. Furthermore, it is possible for rheumatoid factor to give false-positive results for IgM antibodies in the presence of IgG antibodies (14, 20a) .
In the test described here there is no competition between IgG and IgM antibodies, but only between IgM antibodies of other specificities. Furthermore, because of the selection of IgM antibodies by the anti-IgM-coated plate, the virus-antibody complex is allowed to form without interference of any possible rheumatoid factor originally present in the serum to be tested. In accordance with this we did not find any of the rheumatoid factor-containing sera to react positively in ELISA for IgM anti-HAV, although most of them contained anti-HAV when tested by competition ELISA. On the other hand, about three-quarters of the sera were found to give false-positive results when examined for rubella IgM antibodies in an ELISA test in which rubella IgM antibody was measured by attachment to rubella antigen-coated plates.
We believe that the principle described here, with binding of IgM antibodies to anti-IgMcoated plates followed by testing for the specificity of the IgM, is going to be widely used 
